On Tuesday, Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) was 1.01% up from the session before settling in for the closing price of $465.08. A 52-week range for VRTX has been $341.85 – $510.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.16%. When this article was written, the company’s average yearly earnings per share was at -97.83%. With a float of $257.43 million, this company’s outstanding shares have now reached $257.70 million.
Let’s determine the extent of company efficiency that accounts for 5400 employees.
Vertex Pharmaceuticals, Inc. (VRTX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vertex Pharmaceuticals, Inc. stocks. The insider ownership of Vertex Pharmaceuticals, Inc. is 0.26%, while institutional ownership is 92.70%. The most recent insider transaction that took place on Aug 30 ’24, was worth 1,888,216. In this transaction Executive Chairman of this company sold 3,784 shares at a rate of $499.00, taking the stock ownership to the 9,994 shares. Before that another transaction happened on Aug 30 ’24, when Company’s Director sold 646 for $500.00, making the entire transaction worth $323,000. This insider now owns 4,435 shares in total.
Vertex Pharmaceuticals, Inc. (VRTX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted 4.08 earnings per share (EPS) during the time that was better than consensus figure (set at 3.97) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -97.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.33% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Trading Performance Indicators
You can see what Vertex Pharmaceuticals, Inc. (VRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.03, a number that is poised to hit 4.05 in the next quarter and is forecasted to reach 18.59 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc. (VRTX)
Looking closely at Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX), its last 5-days average volume was 0.87 million, which is a drop from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 34.40%. Additionally, its Average True Range was 9.19.
During the past 100 days, Vertex Pharmaceuticals, Inc.’s (VRTX) raw stochastic average was set at 56.79%, which indicates a significant increase from 40.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.69% in the past 14 days, which was lower than the 19.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $478.78, while its 200-day Moving Average is $444.04. However, in the short run, Vertex Pharmaceuticals, Inc.’s stock first resistance to watch stands at $474.26. Second resistance stands at $478.76. The third major resistance level sits at $485.21. If the price goes on to break the first support level at $463.31, it is likely to go to the next support level at $456.86. Now, if the price goes above the second support level, the third support stands at $452.36.
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Key Stats
There are 258,053K outstanding shares of the company, which has a market capitalization of 121.25 billion. As of now, sales total 9,869 M while income totals 3,620 M. Its latest quarter income was 2,646 M while its last quarter net income were -3,594 M.
